TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics is laser-focused on ensuring successful execution of these initiatives throughout 2026
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceLiver market share gains are pure TransMedics execution excellence, period, full stop
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceUpcoming registry publication will demonstrate unequivocal statistical superiority in the most important outcomes after liver transplantation
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceTransMedics achieved our best operational performance to date with these results achieved despite external challenges earlier in the year that were designed to distract and disrupt our sustained and transformational growth
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue for fourth quarter while making substantial investments to fuel growth
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceWe are not seeing competitive dynamic impacting our ability to execute in 2026 and beyond
80% confidenceOCS Liver market share gains represent pure TransMedics execution excellence
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceUpcoming OCS Liver registry publication will show unequivocal statistical superiority in the most important outcomes after liver transplantation
80% confidenceWhat's coming is really the unequivocal drop-the-mic statistical superiority in the most important outcomes after liver transplantation
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceTransMedics is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidence2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceCompany is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidence